32 results about "Glucagon" patented technology

This invention provides a polypeptide or a pharmaceutically acceptable salt thereof that may be useful in the treatment of type 2 diabetes (T2D), diabetes mellitus with obesity, obesity, and hyperlipidemia. [Solution] Provides a long-acting glucagon-like peptide-1 and a human glucose-dependent insulin secretion-stimulating polypeptide (GIP) biagonal agonist polypeptide.

The invention relates to a pharmaceutical composition for use as a medicament, in the oral treatment of a disease, in particular a metabolic disease, said pharmaceutical composition comprising a Glucagon-like peptide-1 receptor agonist (GLP-1), and a system that can buffer the pH of the pharmaceutical composition to a value ranging from 4 to 8.

Provided herein are compositions, systems, kits, and methods for detecting, in a DNA sample from a subject (e.g., overweight or obese subject), the presence of at least one polymorphism in the Neurobeachin (NBEA) gene. In particular embodiments, once at least one such polymorphism is detected, the subject is treated with, or provided with, a Glucagon-like peptide-1 receptor agonist (GLP-1RA).

The present disclosure relates to a drug combination and a method for the prevention and / or the treatment of a liver disease, the combination comprising lanifibranor or a deuterated form thereof and a GLP-1 / GIP / glucagon triple receptor agonist.

Convergent pathways for the preparation of a peptide by solid phase peptide synthesis or liquid phase peptide synthesis, as well as peptide fragments suitable for use in such pathways, are provided. The convergent pathways may be utilized for the synthesis of agonists of the glucagon-like peptide 1 receptor (GLP-1R) such as the peptide component of maridebart cafraglutide.

In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.

Provided is an Akkermansia muciniphila strain including Akkermansia muciniphila LWHK0001, LWHK0002, LWHK0004, LWHK0005, LWHK0006, or LWHK0008. Also provided is a method of Akkermansia muciniphila for increasing glucagon-like peptide-1, including LWHK0001, LWHK0002, LWHK0003, LWHK0004, LWHK0005, LWHK0006, or LWHK0008. Also provided is an Akkermansia muciniphila extract having the effect of increasing glucagon-like peptide-1.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and / or hydrate and / or prodrug of the compound) that modulate (e.g., agonize or partially agonize or antagonize) glucagon-like peptide-1 receptor (“GLP-1R”) and / or the gastric inhibitory polypeptide receptor (“GIPR”). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP-1R and / or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and / or symptoms and / or progression of the disease, disorder, or condition. In some embodiments, the modulation results in an enhancement of (e.g., an increase in) existing levels (e.g., normal or below normal levels) of GLP-1R and / or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) β-arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

This invention describes useful protein-drug conjugates and compositions thereof, for example, for targeting the glucagon-like peptide-1 receptor (GLP1R). In some embodiments, peptide analog payloads and linker-payloads are provided, as well as methods for preparing them. More specifically, GLP1 peptide analogs, antibody-drug conjugates, and compositions comprising an anti-GLP1R antibody and a GLP1 peptide analog payload are provided, as well as methods for treating GLP1R-related conditions.

The present disclosure relates to a compound having a novel structure that binds to the glucagon-like peptide-1 receptor (GLP-1R) and acts as an agonist or a modulator thereof, a preparation method thereof, and uses thereof. The compound of the present disclosure can bind to the GLP-1 receptor and exhibit agonist activity thereof, and thus may be usefully employed for the treatment or prevention of GLP-1 receptor activity-associated diseases.

This invention provides a soybean protein hypoglycemic peptide and its application, belonging to the field of bioactive peptide technology. The sequence of the soybean protein hypoglycemic peptide of this invention is shown as DYPAY or DFPALR. The bioactive peptides DYPAY or DFPALR obtained by screening in this invention exhibit significant dipeptidyl peptidase-IV (DPP-IV) inhibitory activity, effectively increasing the level of endogenous glucagon-like peptide-1 (GLP-1), thereby achieving mechanistic regulation of blood glucose with a clearly defined target. The bioactive peptides of this invention have a clear source, simple structure, are easy to synthesize, and possess good stability and safety, making them suitable for developing functional foods or hypoglycemic-related products, with broad application prospects.

This disclosure relates to the use of compounds and pharmaceutical compositions thereof in the preparation of medicaments for the prevention and / or treatment of myopia. The compounds disclosed herein are medicaments for treating diabetes, selected from at least one of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, insulin sensitizers, or dipeptidyl peptidase-4 inhibitors. This disclosure provides novel compounds for the prevention and / or treatment of myopia, and to further improve efficacy, this disclosure also provides pharmaceutical compositions comprising said compounds.

This invention discloses a dual-activator polypeptide compound and its pharmaceutical uses, belonging to the field of polypeptide pharmaceuticals. The amino acid sequence of the GIP-R and GLP-1R dual-activator polypeptide compound is: Y-Z-EGTFTSDYSI-X2-LDKI-A-Q-B n -X4-X5-VQWLI-X6-GGPSSG-A-PPPS, with the C-terminal amino acid being amidated. The GIP-R and GLP-1R dual-agonist polypeptide compounds of this invention exhibit more significant dual-agonist activity against human glucose-dependent insulinotropic peptide (GIP) and human glucagon-like peptide-1 (GLP-1) receptors. They not only possess hypoglycemic and weight-loss effects but also have a longer half-life and higher bioavailability, avoiding adverse reactions such as nausea and vomiting caused by long-term use of existing drugs. They can be used as effective raw materials for preparing drugs for treating or preventing diabetes or weight-loss drugs.

Methods for intranasal delivery of GLP-1 (glucagon-like peptide-1) drugs, such as tirzepatide (TZP), using drug formulations encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles coated with chitosan (CS) and / or chitosan grafted with polyethylenimine (CS-PEI) under optimized conditions for surface charge alteration and particle size control. The resulting formulations successfully provided dose-dependent body fat reduction in mice, showing significant therapeutic effects.

A method for improving the solubility of a pharmaceutical compound is disclosed, wherein the pharmaceutical compound is insulin, a natural insulin variant, an insulin variant or insulin analog, a GLP-1 agonist, a GIP agonist, a glucagon agonist, an amylin agonist or an incretin mimic. The method involves using a non-nutritive sugar, such as raspberry glycoside, neohesperidin A, dulcitin B, dodecyl-β-D-maltodextrin (DDM), or carhariside, or any combination thereof, in the presence of a solvent such as ethanol or a mixture thereof, followed by removal of the solvent by drying and re-solubilization to generate a water-soluble complex. The complex formed using the disclosed method is also described.

Provided herein, inter alia, are therapies using a Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor and optionally a glucagon-like peptide 1 receptor (GLP-1) agonist. The therapies can be used to treat type 2 diabetes and / or obesity and to promote weight loss.

Described herein are methods and compositions for treatment of diabetes and / or obesity. Bitter oligopeptide molecules formulated for enteric delivery modulate signals involving receptors facing the lumen of the gastrointestinal tract, said signaling related hormones such as glucagon-like peptide-1 (GLP-1) and peptide tyrosine-tyrosine (PYY) that involve inhibition of gastric emptying and appetite. As a novel way to treat diabetes with limited adverse effects the described invention uses body's own endocrine system to treat diabetes, which is an advantage over current therapies that may simply provide disease management without cure or require more radical approaches such as surgical intervention.

The present disclosure relates generally to nucleic acid molecules, e.g., self-replicating RNA (srRNA) expressing glucagon-like peptide 1 receptor (GLP-1R) agonists, as a monogenic or multigenic along with GPCR agonists, GIPR agonists, and GCGR agonists, pharmaceutical compositions and recombinant cells containing the same, as well as the use of such srRNA molecules, recombinant cells, and compositions for activating GLP-1R signaling in a subject. Also provided are methods for preventing and / or treating various health conditions associated with GLP-1R signaling.

The present invention relates to methods for incremental weight loss and to the field of treatment to improve body composition changes and physical function with weight reduction. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), GIP, glucagon, amylin, or by sodium-glucose transport protein 2 (SGLT-2) inhibitors.

The disclosure provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the glucagon and GLP-1 receptors. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

The present disclosure relates to a drug combination and a method for the prevention and / or the treatment of a liver disease, the combination comprising lanifibranor or a deuterated form thereof and a GLP-1 / glucagon dual receptor agonist.

To provide a composition for the prevention, improvement, or treatment of mucositis induced by radiotherapy, chemotherapy, or a combination thereof, comprising a glucagon-like peptide-2 (GLP-2) derivative and / or a sustained-release conjugate thereof. [Solution] The present invention relates to the prophylactic or therapeutic use of GLP-2 and its sustained-release conjugates against mucositis induced by radiotherapy, chemotherapy, or a combination thereof. The GLP-2, its sustained-release conjugates, or compositions comprising the same of the present invention may be applied to the prevention, treatment, and improvement of mucositis induced by radiotherapy and / or chemotherapy.

Provided are dual-target agonist peptides, and more specifically a series of dual-target agonists capable of simultaneously activating the human glucagon-like peptide-1 (GLP-1) receptor and the human glucose-dependent insulinotropic polypeptide (GIP) receptor, as well as pharmaceutical salts and pharmaceutical compositions thereof. These peptides have dual agonist effects and can be used to treat diabetes, obesity, and other related diseases.

The present disclosure provides combinations for reducing weight and / or preventing weight gain in a subject (e.g., an obese subject) comprising three or more (e.g., three or four) of: (i) an amylin analog, (ii) a GLP-1 receptor agonist, (iii) a GIP analog, and (iv) a glucagon analog. As described herein, the combination can be administered to a subject in the same pharmaceutical composition or in separate pharmaceutical compositions (e.g., via concurrent or subsequent administration).

Provided are the methods of use and pharmaceutical compositions of mitochondrial uncouplers and glucagon-like peptide-1 receptor agonists for treating various diseases and conditions, including obesity, T2DM, liver diseases and conditions (e.g., MASH), and cardiovascular diseases and conditions(e.g.,heart failure).

The present invention relates to glucagon derivatives, conjugates thereof, compositions comprising the same, and uses thereof, and in particular to therapeutic uses for metabolic syndrome, hypoglycemia, and congenital hyperinsulinism.

Provided herein are combinations of NLRP3 inflammasome inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists and methods comprising administering to a subject in need thereof such combinations for the treatment of a GLP-1 linked disease and / or a weight disorder.

Methods of use and pharmaceutical compositions of berberine ursodeoxycholate and glucagon-like peptide-1 receptor agonists for treating obesity and related diseases and conditions are provided.